Net Income

For the first time, NCH's heart institute earns national recognition, driven by AI-powered tech and a commitment to world-class care in Southwest Florida.

The nation's top IV therapy franchise reports record growth, but its expansion highlights a booming wellness industry navigating a complex regulatory landscape.

A new pilot program uses AI to find hidden patterns in past cancer trial data, aiming to get the right drugs to the right patients, faster.

Top execs from finance and tech join Relay Resources' board, bringing corporate power to accelerate its disability inclusion and social enterprise goals.

With strong revenue, key AI upgrades, and a top Microsoft award, Blue Yonder is solidifying its market lead as global supply chain pressures intensify.

A new long-acting CBD injection shows major promise for arthritic dogs, and the company is now in talks with the FDA for human applications.

A new 'zero-disruption' plate from TheWell Bioscience aims to solve key challenges in organoid research, promising more reliable data for drug discovery.

Amid market volatility, Lavior is boosting US production and launching dual product lines, a strategic move to ensure stability for clinics and consumers alike.

As Omada Health preps its 2025 results, all eyes are on whether its blend of tech, human coaching, and GLP-1 support can deliver sustainable profits.

Safe Harbor Financial secures a landmark deal with PCCU, boosting revenue by $9M but taking on more risk. A bold move in the evolving cannabis finance world.

Backed by a proven billion-dollar impact model, 14 new startups are using AI, neuroscience, and philanthropy to revolutionize mental healthcare.

With its lead drug in Phase 3, Celldex will update investors at three major conferences, highlighting its immunology pipeline and financial strategy.

Universal Corporation appoints Steven Diel, the mind behind its ingredients push, as CFO, signaling a firm commitment to diversification despite headwinds.

As it marks its 40th year, the legal finance giant's impressive 3.0x return on capital highlights the growing appeal of legal assets as a stable asset class.

Guardforce AI aims to acquire a leading speech therapy platform, signaling a major strategic pivot from secured logistics to the booming AI healthcare market.

A landmark deal will see Takeda use Iambic's AI platform to slash drug development timelines and fast-track new medicines for cancer and other diseases.

After a year-long restructuring, SVCV launches asset manager NextRock to acquire 100 companies and build a cross-industry empire from finance to fashion.

With five conferences in its sights, Voyager Therapeutics is making a major push to win over investors ahead of a pivotal year for its neurological pipeline.

The private jet operator posted record revenue with fewer planes, achieving its first-ever quarter of positive Adjusted EBITDA in a major turnaround.

A new report reveals AI-themed ads failed to connect with viewers, while heartfelt, human-centric stories from brands like the NFL and Budweiser won the night.